ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
Key PointsThe executive disposed of 3,313 shares on July 2, 2026, for a total transaction value of about $285,000...
Nasdaq News: Markets
More News
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
Key PointsAn ANI Pharmaceuticals executive reported selling 2,850 shares directly for about $240,000 on June 29, 2026...
Nasdaq News: Markets
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
Zacks
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
Zacks
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth
ANIP bets on Cortrophin Gel to power 2026 growth as rare disease sales become the majority of revenues. What must keep working?
Zacks
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
Zacks
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.